By Elric Langton | 15 November 2022
I have a financial interest in Poolbeg Pharma.
Poolbeg Pharma (AIM: POLB OTCQB: POLBF) is developing some juicy newsflow this month. Today the clinical-stage infectious disease pharmaceutical company announced it had been awarded β¬2.3m (over three years - unsure of the split), a milestone, the first non-dilutive fundingβ¦